Searched for
MOLBIO DIAGNOSTICS BUY SELL HOLD
Selling gold after price rise: Have you factored in capital gains tax you will have to pay? Know how you will be taxed on selling Rs 10 lakh worth of goldWhen selling old gold jewellery, be aware that it comes with capital gains tax and Goods and Services Tax implications. Long-term capital g...- These large- and mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos have upside potential of up to 28%, according to analystsWith each passing day, things are getting more complicated in the Gulf region – as well as in the market. When will things get sorted out? ...
- Quote of the day by Daniel Kahneman: "When deciding to sell, people have control over whether to give themselves pleasure or give themselves pain, and they tend to give themselves pleasure. In other words, they tend to sell winners and hang on to losers. It turns out to be a bad idea."Daniel Kahneman’s behavioural economics insights explain why investors often sell winning stocks too early while holding losing investments...
- Molbio Diagnostics shares rally 30% in 2 days, jump 80% since debut. What lies ahead?Molbio Diagnostics shares have surged nearly 30% in two sessions, extending their post-listing gains to around 80% from the IPO price. The ...
- DHR Holdings leases 1.8 lakh sq ft in BengaluruDHR Holding India has leased nearly 1.8 lakh square feet of office space in Bengaluru. The company secured three floors at Sumadhura Capito...
- CLSA sees 29% downside in Meesho despite a 19% YTD rally. Buy, sell or hold?CLSA maintained an Underperform rating on Meesho with a Rs 150 target, citing stretched valuations and optimism around advertising monetisa...
- Why DSP Mutual Fund's Chirag Dagli is betting on CDMO, hospitals and smallcap healthcare stocksAt the same time, the fund is evaluating hospital expansion, hybrid diagnostics businesses and valuations to identify healthcare companies ...
- EBay probes how banned gender-test kits were available in India, listings removedEBay has launched an internal review of its safeguards after Reuters found gender-prediction kits being offered for delivery to India, wher...
- Broadcom’s $230 billion AI opportunity: Buy, Sell or Hold on the AVGO stock?Broadcom’s AI semiconductor revenue surged 221%, driving strong fiscal growth and ambitious future targets. However, elevated valuation, ma...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 20%, according to analystsInvesting, a wise man once said, is a journey; one that needs to be managed carefully. Remember two things: One, there is never a “perfect ...
- Tough task: Staying invested in businesses while ignoring noise called Gulf war; 6 mid-cap stocks with upside potential of up to 23%Trying to time the market turns volatility into something that beats an investor twice: Once on the way down, and once on the way up. So, i...
- How 90% IPOs in August beat volatile India market to return up to 72% after listingIn August, a majority of newly listed IPOs saw a successful debut, outpacing the broader market. Approximately ninety percent of these list...
- Demand for vaccines surges as H1N1, other influenza cases see a sharp riseDemand for flu vaccines has significantly increased this year. At-home vaccination services are seeing a substantial rise in bookings. Rapi...
- Corporates urge employees to stay alert as H1N1 cases surgeH1N1 cases have increased significantly, and monsoon fevers are at seasonal highs. Companies are issuing safety guidelines and advising emp...
- Molbio Diagnostics shares rally 6% after strong debut. What should investors do?Molbio Diagnostics made a strong debut, beating grey market expectations. Experts remain positive on the company’s molecular diagnostics le...
- Molbio Diagnostics shares list at 21% premium over IPO price on BSE, NSEMolbio Diagnostics Share Price: Molbio Diagnostics made a strong stock market debut, listing at a 21.44% premium over its IPO price of Rs 8...
- Molbio Diagnostics IPO allotment likely today; GMP at 20% — Here’s how to check statusMolbio Diagnostics IPO allotment is expected on Thursday after the Rs 939.70-crore issue was subscribed 70.26 times. With a grey market pre...
- Molbio Diagnostics IPO Day 3: GMP hints at 17% listing gain, issue booked nearly 5x. Should you participate?Molbio Diagnostics IPO: Point-of-care molecular diagnostics company Molbio Diagnostics saw strong investor response for its IPO, drawing as...
- Molbio Diagnostics IPO Day 2: GMP hits at 17% listing gains. Should you bid?Molbio Diagnostics IPO GMP: The Molbio Diagnostics IPO entered its second day with strong investor interest, as the grey market premium (GM...
- Molbio Diagnostics IPO opens: Should you subscribe for Rs 940 crore issue?Molbio Diagnostics IPO GMP: Market analysts have recommended subscribing to the issue, noting that Molbio Diagnostics’ valuations are broad...
Load More
